Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.89 |
| ▸ | PPARG | P37231 | 10/20 | 0.89 |
| ▸ | PPARD | Q03181 | 2/20 | 0.74 |
| ▸ | ACE | P12821 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8538273 | 1.00 | PPARA (0.89) | PPARAPPARGPPARDACECYP1A2 | |
| SCHEMBL7331137 | 1.00 | PPARA (0.89) | PPARAPPARGPPARDACECYP1A2 | |
| SCHEMBL3362562 | 0.90 | PPARA (0.90) | PPARAPPARGPPARDACE | |
| SCHEMBL3582418 | 0.90 | PPARA (0.90) | PPARAPPARGPPARDACE | |
| SCHEMBL5853138 | 0.90 | PPARA (0.90) | PPARAPPARGPPARDACE | |
| SCHEMBL4966773 | 0.89 | PPARA (0.84) | PPARAPPARGPPARDACE | |
| SCHEMBL7314920 | 0.89 | PPARA (0.71) | PPARAPPARGPPARDACECYP1A2 | |
| Hydrochloric Acid SCHEMBL28347115 | 0.88 | PPARA (0.88) | PPARAPPARGPPARDACE | |
| Hydrochloric Acid SCHEMBL28347112 | 0.88 | PPARA (0.88) | PPARAPPARGPPARDACE | |
| SCHEMBL1278177 | 0.88 | PPARA (0.89) | PPARAPPARGPPARDACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612441-B2 | Polypeptide and therapeutic uses thereof | VITALIXIR (BEIJING) CO., LTD (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-3127914-B1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVES | UNIV MIYAZAKI (JP) | 2025-12-17 | — | — | EP | disclosed |
| CN-118679179-B | Long-acting GLP-1 polypeptide compound, composition and application thereof | 内蒙古博睿精创科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-113614102-B | Novel polypeptides and therapeutic uses thereof | 鸿绪生物医药科技（北京）有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118126124-A | Bioactive polypeptide with QRRAD structure, composition and application thereof | 深圳市肽金生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116650424-A | Novel polypeptide formulations and therapeutic uses thereof | 鸿绪生物医药科技（北京）有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230263896-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | VITALIXIR (BEIJING) CO., LTD (CN) | 2023-08-24 | — | — | US | disclosed |
| US-4716147-A | NATRIURETIC POLYPEPTIDES | MONSANTO COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| US-4684621-A | OLIGOPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-04 | — | — | US | disclosed |
| US-4684620-A | Cyclic polypeptides having mu-receptor specificity | GIBSON-STEPHENS NEUROPHARMACEUTICALS, INC. (US) | 1987-08-04 | — | — | US | disclosed |
| US-4658015-A | ANTAGONIST OF VASSOPRESSIN AND OXYTOCIN | SMITHKLINE BECKMAN CORPORATION (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0192742-A1 | CYCLIC POLYPEPTIDES HAVING MU-RECEPTOR SPECIFICITY | GIBSON-STEPHENS NEUROPHARMACEUTICALS, INC. (US) | 1986-09-03 | — | — | EP | disclosed |
| US-4604378-A | CYCLIC POLYPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0182627-A2 | Basic V1-vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-28 | — | — | EP | disclosed |
| WO-1986001516-A1 | CYCLIC POLYPEPTIDES HAVING MU-RECEPTOR SPECIFICITY | GIBSON-STEPHENS NEUROPHARMACEUTICALS, INC. (US) | 1986-03-13 | — | — | WO | disclosed |
| US-4543349-A | Basic heptapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1985-09-24 | — | — | US | disclosed |
| US-4515920-A | Synthesis of peptides and proteins | THE ROCKEFELLER UNIVERSITY (US) | 1985-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612441-B2 | Polypeptide and therapeutic uses thereof | VIP, GCG, GLS | PPARA 3619/4885PPARG 1881/4885PPARD 4337/4885 |
| US-20230263896-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | VIP, IAPP, LNPEP | PPARA 2927/4885PPARG 3932/4885PPARD 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.